CRVSHealthcare · BiotechnologyThe 8 Wall Street analysts covering Corvus Pharmaceuticals, Inc. hold a median 12-month price target of $32 — +127.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Corvus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (84): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (33): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CRVS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +127.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Apr 2026 | Goldman Sachs | Initiates | Buy | $40 |
| 13 Mar 2026 | Oppenheimer | Reiterates | Outperform | — |
| 22 Jan 2026 | Jefferies | Maintains | Buy | — |
| 21 Jan 2026 | Barclays | Maintains | Overweight | — |
| 21 Jan 2026 | Oppenheimer | Maintains | Outperform | — |
| 20 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Oct 2025 | Barclays | Initiates | Overweight | — |
| 20 May 2025 | Mizuho | Maintains | Outperform | — |
| 9 May 2025 | Oppenheimer | Reiterates | Outperform | — |
| 26 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Mar 2025 | Oppenheimer | Maintains | Outperform | — |
| 14 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Jan 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 13 Nov 2024 | Oppenheimer | Reiterates | Outperform | — |
| 16 Sept 2024 | Ladenburg Thalmann | Maintains | Buy | — |
| 7 May 2024 | Oppenheimer | Maintains | Outperform | — |
| 1 Apr 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 27 Mar 2024 | Mizuho | Maintains | Neutral | — |
| 20 Mar 2024 | Oppenheimer | Maintains | Outperform | — |
| 7 Sept 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRVS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 20% of US stocks
Cheaper than 88% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 25% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Corvus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of Corvus Pharmaceuticals' (CRVS) Q2 2026 earnings call. The item consists solely of the earnings call transcript headline and source.
Why it matters — A CRVS watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly results and management discussion.
Corvus Pharmaceuticals reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor. The company outlined expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and asthma.
Why it matters — A CRVS watcher would care because the company's increased spending is tied to advancing soquelitinib across multiple key clinical programs and upcoming milestones.
Corvus Pharmaceuticals provided a business update and reported second-quarter 2026 financial results. Enrollment in its soquelitinib registrational Phase 3 trial for relapsed/refractory peripheral T-cell lymphoma and Phase 2 atopic dermatitis trials is on track, and Phase 1 data on soquelitinib in atopic dermatitis was presented at the Society for Investigative Dermatology annual meeting. The company held $215.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, providing funding into the second quarter of 2028.
Why it matters — A CRVS watcher would care because the update confirms progress in two clinical programs for soquelitinib and indicates the company has a cash runway into 2Q28 to support those trials.
Corvus Pharmaceuticals announced it will release its second quarter 2026 financial results and provide a business update on August 6, 2026, followed by a conference call and webcast at 4:30 pm ET / 1:30 pm PT.
Why it matters — The announcement signals an upcoming opportunity for CRVS watchers to receive the latest financial performance data and management commentary on the company's progress.
The 8 Wall Street analysts covering Corvus Pharmaceuticals, Inc. have a median 12-month price target of $32, with estimates ranging from $27 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Corvus Pharmaceuticals, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Corvus Pharmaceuticals, Inc. 54 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Corvus Pharmaceuticals, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (84 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +127.1% from the last close, and Ticker Nerd's factor model ranks Corvus Pharmaceuticals, Inc. 54 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Corvus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $42 over the next 12 months.
Corvus Pharmaceuticals, Inc. returned +153.9% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing investigational therapies that modulate immune pathways for cancer and immune-mediated diseases.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Corvus Pharmaceuticals' (CRVS) Q2 2026 earnings call. The item consists solely of the earnings call transcript headline and source.
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing investigational therapies that modulate immune pathways for cancer and immune-mediated diseases. Its primary emphasis is on ITK inhibition through its lead product candidate, soquelitinib, an oral small molecule designed to selectively target interleukin-2-inducible T cell kinase, influencing T cell differentiation and function. This approach aims to address conditions such as peripheral T cell lymphomas, atopic dermatitis, autoimmune lymphoproliferative syndrome, and other inflammatory disorders by promoting Th1 immune responses while suppressing Th2 and Th17 pathways. The company also advances other immune modulators, including ciforadenant, an A2A receptor antagonist for metastatic renal cell cancer, and mupadolimab, a monoclonal antibody for non-small cell lung cancer, often in combination with checkpoint inhibitors. Founded in 2014 and headquartered in South San Francisco, California, Corvus Pharmaceuticals Inc. operates through clinical trials, strategic collaborations like those with Angel Pharmaceuticals for greater China, and preclinical programs targeting adenosine pathways and CXCR2. It plays a specialized role in immuno-oncology and immunology within the biopharmaceutical sector.
CEO Dr. Richard A. Miller M.D. · 37 employees · United States · https://www.corvuspharma.com